ArticleFrontiers in oncology2022

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China.

Hao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.